Quantifying the Value Proposition of RBQM

On-Demand Webinar

What is the real financial value of Risk-Based Quality Management?

Kenneth Getz and Abigail Dirks from the Tufts Center for the Study of Drug Development alongside Sylviane de Viron from CluePoints present one of the industry's first peer-reviewed studies quantifying the financial value of Risk-Based Quality Management.

Drawing on real-world data from 18 oncology clinical trials, the research reveals how organizations achieved up to 23x ROI and shortened clinical phase durations by up to 19%.

What You Will Learn

• How to demonstrate the financial value of RBQM

• How to support investment decisions with peer-reviewed evidence

• Why time savings deliver greater value than monitoring cost reductions

Access the recording now.